Display options
Cite
Koelzer VH, Buser T, Willi N, et al. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016;4:47doi: 10.1186/s40425-016-0151-z.
Koelzer, V. H., Buser, T., Willi, N., Rothschild, S. I., Wicki, A., Schiller, P., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016). Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. Journal for immunotherapy of cancer, 447. https://doi.org/10.1186/s40425-016-0151-z
Koelzer, Viktor H, et al. "Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy." Journal for immunotherapy of cancer vol. 4 (2016): 47. doi: https://doi.org/10.1186/s40425-016-0151-z
Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016. PMID: 27532022; PMCID: PMC4986338.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016.

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.

Journal for immunotherapy of cancer

Viktor H Koelzer, Tobias Buser, Niels Willi, Sacha I Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D Mertz

Affiliations

  1. Cantonal Hospital Baselland, Institute of Pathology, Mühlemattstrasse 11, CH-4410 Liestal, Switzerland ; Translational Research Unit (TRU), Institute of Pathology, University of Bern, Murtenstrasse 31, CH-3010 Bern, Switzerland.
  2. Division of Medical Oncology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
  3. Cantonal Hospital Baselland, Institute of Pathology, Mühlemattstrasse 11, CH-4410 Liestal, Switzerland.
  4. Cantonal Hospital Baselland, Mühlemattstrasse 11, CH-4410 Liestal, Switzerland.

PMID: 27532022 PMCID: PMC4986338 DOI: 10.1186/s40425-016-0151-z

Abstract

BACKGROUND: Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash and pruritus. Rarely life threatening complications such as Steven's Johnson syndrome or toxic epidermal necrolysis may occur.

CASE PRESENTATION: Here we report the uncommon event of a drug-induced transient acantholytic dermatosis (Grover's disease) in a 73-year-old Caucasian male treated with ipilimumab for metastatic melanoma. Five weeks after initiation of therapy, the patient developed a widespread polymorphic papulovesicular dermatosis on the trunk and proximal extremities with intense pruritus. Skin biopsy showed acantholytic dyskeratosis with interface dermatitis consistent with a Grover's-like drug eruption.

CONCLUSIONS: These findings should raise awareness for uncommon immune-related dermatological toxicities of immunomodulatory antibodies targeting the CTLA-4 signaling axis. We recommend biopsies of unexpected skin lesions to rapidly identify dermatological adverse events of immune checkpoint inhibitors.

Keywords: Autoimmunity; Drug eruption; Grover’s disease; Immune checkpoint inhibitors; Immunotherapy; Ipilimumab; Melanoma; Transient acantholytic dermatosis

References

  1. Arch Pathol Lab Med. 2009 Sep;133(9):1490-4 - PubMed
  2. J Am Acad Dermatol. 2012 Dec;67(6):1265-72 - PubMed
  3. Melanoma Res. 2015 Jun;25(3):265-8 - PubMed
  4. J Clin Oncol. 2012 Jul 20;30(21):2691-7 - PubMed
  5. J Cutan Pathol. 1993 Oct;20(5):407-10 - PubMed
  6. Br J Dermatol. 2012 Nov;167(5):1153-60 - PubMed
  7. J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):206-9 - PubMed
  8. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  9. Br J Dermatol. 2014 Nov;171(5):1236-7 - PubMed
  10. Mayo Clin Proc. 1999 Mar;74(3):229-34 - PubMed
  11. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  12. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 - PubMed
  13. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  14. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  15. Ann Oncol. 2015 Dec;26(12):2375-91 - PubMed
  16. Int J Dermatol. 1997 Jun;36(6):476-7 - PubMed
  17. Scientifica (Cairo). 2013;2013:857519 - PubMed
  18. J Am Acad Dermatol. 2014 Jul;71(1):161-9 - PubMed

Publication Types